Influence of chronic hepatic failure on disposition kinetics of valproate excretion through a phase II reaction in rats treated with carbon tetrachloride by Khemawoot Phisit et al.
Influence of chronic hepatic failure on
disposition kinetics of valproate excretion
through a phase II reaction in rats treated
with carbon tetrachloride
著者 Khemawoot Phisit, Maruyama Chiharu, Tsukada
Hirotaka, Noda Hiroyo, Ishizaki Junko,
Yokogawa Koichi, Miyamoto Kenichi
journal or
publication title








Influence of chronic hepatic failure on disposition kinetics of valproate 
excretion through a phase II reaction in rats treated with carbon 
tetrachloride  
 
Phisit Khemawoota, Chiharu Maruyamab, Hirotaka Tsukadab, Hiroyo Nodab, 
Junko Ishizakic, Koichi Yokogawaa, b and Ken-ichi Miyamotoa, b, * 
 
 
a Department of Medicinal Informatics, Division of Cardiovascular 
Medicine, Graduate School of Medical Science, Kanazawa University, 13-1 
Takara-machi, Kanazawa 920-8640, Japan 
b Department of Hospital Pharmacy, School of Medicine, Kanazawa 
University, 13-1 Takara-machi, Kanazawa 920-8641, Japan 
c Department of Pharmacy and Health Science, Graduate School of Natural 
Science and Technology, Kanazawa University, Kakuma, Kanazawa, 920-
1192, Japan 
 
*Corresponding author: Ken-ichi Miyamoto, Ph. D., Prof. 
Department of Hospital Pharmacy, School of Medicine, Kanazawa 
University, 13-1, Takara-machi, Kanazawa 920-8641, Japan. 






Abstract: We examined the influence of chronic hepatic failure on the 
disposition kinetics of valproate (VPA) excretion via a phase II reaction in 
rats treated with carbon tetrachloride (1.0 mg/kg, s.c., 3 times a week) for 2 
or 3 months.  There was no significant difference in the plasma 
concentration-time courses of VPA among control and two treated groups 
up to 120 min after i.v. administration of VPA (75 mg/kg), but 
subsequently the plasma concentrations of the treated groups declined 
significantly below the control levels.  Expression of Mrp2 mRNA in the 
liver of the treated groups was significantly lower than in the control group; 
conversely that in the kidney was significantly higher.  The enzyme 
activity of UGTs in the liver of the treated groups decreased significantly, 
but UGT1A8 mRNA expression in the duodenum was increased about 3-
fold. Cumulative excretion of VPA glucuronide (VPA-G) in bile of the 
treated groups was significantly reduced, while that in urine was markedly 
increased. In conclusion, the area under the VPA plasma concentration-
time curve is significantly decreased in rats with chronic hepatic failure 
owing to increased excretion of VPA-G via the kidney as a result of 
induction of Mrp2, and inhibition of enterohepatic circulation of VPA-G. 
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To select an appropriate drug therapy for patients with hepatic failure, it 
is important to understand the changes of drug disposition kinetics in such 
patients.  It is well known that drug metabolism involves phase I and/or 
phase II reactions.  In humans, phase I reactions are mediated 
predominantly by five families of cytochrome P450 (CYP) species, 
CYP1A, CYP2C, CYP2D, CYP2E and CYP3A.  All the isoforms differ in 
their patterns of drug-metabolizing activity [1], and the amounts of the 
isoforms in the liver are altered in conditions involving hepatic failure [2]. 
We have shown that the degree of increase of serum AST activity can 
be used to predict the decrease of the total clearance (CLtot) in rats with 
acute hepatic failure [3, 4].  Further, we showed that serum albumin levels 
can be used to predict appropriate dosages of hepatically metabolized drugs 
in patients with chronic hepatic failure [5].  Those reports dealt with the 
influence of the degree of hepatic failure on phase I reactions involving 
CYPs.   
Phase II reactions include conjugation reactions such as 
glucuronidation and sulfation, as well as reactions with glutathione, glycine, 
etc.  Glucuronide conjugation is catalyzed by UDP-
glucuronosyltransferase (UGT), which has many isoforms, such as UGT1 
(for phenolic hydroxyl groups and bilirubin) and UGT2 (for steroid 
compounds) [6].  Generally, hepatic failure has little influence on the 
disposition kinetics of drugs metabolized by glucuronidation.  However, 
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there is still little information about the change of disposition kinetics of 
drugs that are excreted in bile and urine after glucuronidation in patients 
with hepatic failure.  The major metabolic pathway of valproate (VPA) is 
glucuronidation by UGTs, followed by excretion into bile; β-oxidation and 
ω-hydroxylation also occur as minor pathways [7].   
In this study, we aimed to clarify the influence of chronic hepatic 
failure on phase II reactions by examining the disposition kinetics of VPA 
as a model drug in rats with treated with carbon tetrachloride (CCl4).   
 
 
Materials and methods 
 
Materials    
 
Sodium valproate, 3,3-dimethylglutaric acid (DMGA) and carbon 
tetrachloride (CCl4) were purchased from Wako Pure Chemicals Co., Ltd. 
(Osaka, Japan).  N-(tert-Butyldimethylsilyl)-N-methyltrifluoroacetamide 
(MTBSTFA) was purchased from Tokyo Kasei Kogyo Co. Ltd. (Tokyo, 
Japan).  All other chemicals were of reagent grade.   
 
Animal experiments   
 
All animal experiments were performed in accordance with the 
guidelines of the Institutional Animal Care and Use Committee of the 
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University of Kanazawa.  Model rats for chronic hepatic failure were 
prepared by subcutaneous administration of CCl4 and used at 48 h after the 
last administration.  A dose of 2 mL/kg of 50% CCl4 solution in corn oil 
were administered to male Wistar rats (7 weeks old, Nippon SLC Co., Ltd., 
Hamamatsu, Japan) 3 times/week (Monday, Wednesday and Friday), for 2 
or 3 months.  The treated rats for 2 or 3 months were 15 weeks old (body 
weight 254 ± 16 g, the mean ± sd of three rats) or 17 weeks old (280 ± 15 
g), respectively.  Untreated control rats received corn oil alone for 3 
months were 17 weeks old (433 ± 16 g).  A 100 μL aliquot of VPA (75 
mg/kg) in normal saline was injected via the femoral vein.  Blood samples 
(300 μl each) were collected at designated time intervals from the jugular 
vein under light ether anesthesia.  Plasma was separated by centrifugation 
at 3000 xg for 10 min and stored at -30°C.  The gas chromatography-mass 
spectrometric (GC-MS) assay of VPA in plasma, bile and urine was carried 
out using reported methods.   
 
Determination of laboratory data   
 
Measurements of laboratory data for plasma samples were conducted at 
SRL Co. Ltd. (Tokyo, Japan).   
 




Concentrations of VPA in plasma, bile and urine were determined by GC-
MS (Model GC-17 system Class 5000, Shimadzu, Kyoto, Japan).  The assay 
for VPA was carried out according to Darius and Meyer [8].  The extraction 
solvent for VPA was ethyl acetate containing 2.5 µg/mL DMGA as an 
internal standard.   
Aliquots of 100 µl of sample plasma, urine and bile were each mixed with 
100 µL of 1 M NaH2PO4 buffer (adjusted to pH 5.0) and 1000 µL of ethyl 
acetate containing the internal standard.  The mixture was shaken for 20 min 
and centrifuged for 5 min at 2800 X g.  The supernatant organic phase was 
transferred to another glass tube and preconcentrated to approximately 100 µL 
under a stream of nitrogen gas at room temperature.  Then 40 µL of N-(tert-
Butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) was added to 
the residue, and the mixture was shaken vigorously.  The sample was 
transferred to an automated-sampler microvial, and incubated for 3 h at room 
temperature.  An aliquot (1 µL) of the sample was injected into the GC-MS 
system.   
 Analyses were carried out in the selected-ion monitoring mode, 
monitoring ions at m/Z 201 and m/Z 331 for VPA and DMGA, respectively.  
Chromatographic separation of VPA was achieved with a methyl siloxane-
crosslinked capillary column (HP-1; 25 m x 0.2 mm I.D.; Hewlett-Packard, 
USA) in a gas chromatograph equipped with a splitless injector.  The oven 
temperature was set at 60°C for 1 min and programmed to 90°C at 30°C/min, 
to 150°C at 5°C/min and then to 250°C at 40°C/min.  The final temperature 
was maintained for 10 min. 
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 For the estimation of glucuronides, plasma, urine and bile samples were 
incubated with β-glucuronidase/arylsulfatase at 37°C for 70 min, and VPA 
was extracted and analyzed as described above.  The concentration of the 
glucuronide of VPA (VPA-G) was obtained by subtracting the concentration 
of the unconjugated form from that of the hydrolysate.   
 
Reverse transcription-polymerase chain reaction (RT-PCR) assay 
 
Total RNA was isolated from the liver, kidney and duodenum by using 
an Isogen Kit (Wako Pure Chemicals Co., Ltd).  Synthesis of cDNA from 
the isolated total RNA was carried out using RNase H-reverse transcriptase 
(GIBCO BRL, Rockville, MD).  Reverse transcription (RT) reactions 
were carried out in a solution of 40 mM KCl, 50 mM Tris-HCl (pH 8.3), 6 
mM MgCl2, 1 mM DTT, 1 mM each of dATP, dCTP, dGTP, and dTTP, 10 
units of RNase inhibitor (Promega, Madison, WI), 100 pmoL of random 
hexamer, total RNA and 200 units of the Moloney murine leukemia virus 
reverse transcriptase (Gibco-BRL, Berlin, Germany) in a final volume of 
50 µL at 37°C for 120 min.  Polymerase chain reaction (PCR) was carried 
out in a final volume of 20 µL, containing 1 µL of RT reaction mixture, 50 
mM KCl, 20 mM Tris-HCl (pH 8.3), 2.5 mM MgCl2, 0.2 mM each of 
dATP, dCTP, dGTP, and dTTP, 1 µM each of the mixed oligonucleotide 
primers, and 1 unit of Taq DNA polymerase (Gibco-BRL).  Reported 
primers were used for rat UGT1A1, rat UGT1A6, rat UGT2B1 [9], rat 




Preparation of liver microsomes   
 
For preparation of microsomes, the liver was homogenized in three 
volumes of 100 mM Tris-HCl buffer (100 mM KCl, 1 mM EDTA, pH 7.4).  
Microsomes were prepared as reported previously [3] and stored at -80°C 
until use.  Protein contents were measured according to the method of 
Lowry et al [13]. 
 
Measurement of UGT activity   
 
An aliquot of 100 μL of 1.8 mM 4-nitrophenol, 50 mM MgCl2, 0.5 M 
Tris-HCl buffer (pH 7.4) and 4 mg/mL of liver microsomes was 
preincubated in a tube at 37°C for 3 min, then 50 μL of the reaction buffer 
(containing 20 mM UDP-glucuronic acid) was added.  The whole was 
incubated at 37°C for 10 min, then cooled in an ice bath, and 100 μL of 
cold acetonitrile was added.  The reaction solution was centrifuged at 
10000 xg for 20 min at 4°C, and the absorbance of the supernatant was 
measured at 405 nm.   
 




Pharmacokinetics parameters were estimated according to model-
independent moment analysis as described by Yamaoka et al. [14].  The 
data were analyzed by the use of Student’s t-test to compare the unpaired 
mean values of two sets of data.  The number of determinations is noted in 
each table and figure.  A value of P < 0.01 was taken to indicate a 
significant difference between sets of data.  The electrophoresis results 





Biochemical data in CCl4-treated rats 
 
Table 1 shows the serum biochemical parameters associated with 
chronic hepatic failure in rats treated with 1.0 mL/kg CCl4 3 times/week for 
2 or 3 months.  The AST, ALT and ALP levels were increased 
significantly in both treated groups.  Total bilirubin increased time-
dependently during the administration of CCl4.  In contrast, the level of 
serum albumin and the A/G ratio were significantly decreased.   
 
Expression of mRNAs and enzyme activity of UGTs  
 
Figure 1 shows the expression of UGT mRNAs (UGT1A1, 1A6, 1A7, 
1A8 and 2B1) in liver and duodenum of rats with chronic hepatic failure.  
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The expression levels of UGT1A7 mRNA in liver of rats with chronic hepatic 
failure were significantly higher than that in the control rats, while those of 
UGT1A1 was significantly lower.  The expression levels of UGT1A6 
mRNA in duodenum of rats with chronic hepatic failure were significantly 
lower than that in the control rats, whereas those of UGT1A8 mRNA was 
about 3 times higher.  
Figure 2 shows the relative activity of UGTs in the liver of rats with 
chronic hepatic failure.  The activity of UGTs in the liver of rats treated with 
CCl4 for 2 or 3 months was significantly decreased compared with that of the 
control rats.    
  
Expression of drug transporter mRNA 
 
Figure 3 shows the expression of Mrp2 mRNA in liver and kidney of rats 
with chronic hepatic failure.  The expression levels of Mrp2 in liver of rats 
with chronic hepatic failure were significantly lower than that in the control 
rats, while those in kidney were significantly higher.   
 
Plasma concentration-time courses of VPA in rats with chronic hepatic 
failure 
 
Untreated rats and CCl4-treated rats at 48 h after the last CCl4 treatment 
(for 2 or 3 months) were intravenously injected with VPA (75 mg/kg).  As 
shown in Fig. 4, there was no significant difference in the plasma 
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concentration-time courses of VPA up to 120 min after the administration 
among the three groups.  However, subsequently the plasma concentrations 
of VPA in the CCl4-treated rats decreased significantly compared with that of 
the control rats.  The pharmacokinetic parameters of VPA are summarized in 
Table 2.  The AUC0-360 value of the rats treated for 2 or 3 months was 
significantly decreased compared with that of the control rats, and the value of 
total clearance (CLtot) was significantly increased.  There was no significant 
difference in the distribution volume at the steady-state (Vdss) among the three 
groups.   
 
Biliary and urinary excretions of VPA and VPA-G 
 
Fig. 5 shows the cumulative excretion levels (percent of dose) of VPA 
and VPA-G in the bile and urine during 6 h after an i.v. administration of 
VPA in control rats and rats treated with CCl4 for 3 months.  The 
cumulative amounts of VPA in the bile and urine of both groups were small 
(about 1-2 %), but the cumulative amount of VPA-G in the bile of the 
control group was about two times higher than that in the urine of the 
control group.  The cumulative amount of VPA-G in the bile of the treated 
group was markedly decreased; conversely the cumulative amount of VPA-
G in the urine of the treated group was significantly increased to about 





In this study, in order to examine the change in the disposition kinetics 
of drugs eliminated by phase II metabolic reaction in chronic hepatic 
failure, we used VPA as a model drug because it is excreted mainly via 
glucuronidation.  VPA is taken up into the liver, where it is converted to 
the glucuronide conjugate, which is excreted via Mrp2 transporter into the 
bile and urine.  
We examined the enzyme activity of UGTs in the control and CCl4-
treated groups.  It is reported that the amounts of UGT mRNA isoforms in 
liver of rats are variable [15], but the enzyme activity of UGTs is 
predominantly dependent on the expression of UGT1A1, 1A6 and 1A7 
mRNAs [16].  In this study, the mRNA levels of UGT1A6 and 1A7 were 
significantly increased in the liver of rats with chronic hepatic failure, 
whereas that of UGT1A1 was significantly decreased (Fig. 1).  Daidoji et 
al. [17] reported that the expression of UGT1A1 mRNA in normal rat liver 
is higher than that of UGT1A6 mRNA, while UGT1A7 mRNA is only 
slightly expressed.  We also confirmed that the expression of UGT1A1 
mRNA in liver is the highest among the three isoforms (data not shown).  
Therefore, the enzyme activity of UGTs in the treated groups was decreased 
compared with that in the control group, owing to the decreased expression 
of UGT1A1 mRNA, in spite of increased expression of UGT1A7 mRNA 
(Fig. 2).  It is reported that the UGT isoforms catalyzing VPA 
glucuronidation in humans are UGT1A6, UGT1A9 and UGT2B7 
(corresponding in rat UGT2B1), but the activity of UGT1A9 in liver is low 
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[18].  Therefore, UGT2B1 is the main determinant of the activity level of 
UGTs for VPA glucuronidation in rats, and so it appears that VPA 
glucuronidation is little influenced by chronic hepatic failure, as judged 
from the unchanged expression of UGT2B1 mRNA.     
We found that the expression of UGT1A8 mRNA in the duodenum is 
increased to about three times the normal level by chronic hepatic failure, 
whereas that in the liver is unchanged (Fig. 1).  UGT1A8 is highly 
expressed in intestine, where it acts to block enterohepatic recirculation of 
drugs that have undergone glucuronidation and subsequent hydrolysis of 
the glucuronide by β-glucuronidase [18].  Therefore, regeneration of VPA 
from VPA-G in the intestinal tract is likely to be minor in rats with chronic 
hepatic failure, because UGT1A8 is induced. 
From the above results, we might predict that the plasma concentration 
of VPA after i.v. administration to rats with chronic hepatic failure would 
not be much changed compared with that of the control rats.  However, as 
shown in Fig. 4, although there was no significant difference in the plasma 
concentration of VPA at 2 h after administration among the three groups, 
subsequently, the levels in the CCl4-treated groups fell to about 1/10 of that 
in the control group.  This result suggests that the disposition kinetics of 
VPA is only slightly influenced by the glucuronidation activity in the liver, 
whereas it is considerably influenced by the inhibition of enterohepatic 
circulation owing to the induction of UGT1A8.  This would be consistent 
with the reported plasma concentration-time courses of VPA after i.v. 
administration in normal rats with or without bile duct cannulation [19].   
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Moreover, we examined the influence of chronic hepatic failure on the 
biliary and urinary excretions of VPA.  We found that the VPA was only 
slightly excreted into the bile and urine, whereas VPA-G was almost 
entirely excreted (Fig. 5).  Yamamura et al. [20] reported that VPA-G is 
mainly excreted into bile, but we found that VPA-G was excreted into both 
bile (about 60%) and urine (about 30%) in the control rats.  However, in 
the treated rats, excretion of VPA-G into the bile was greatly decreased 
compared with the control rats, while that into the urine was greatly 
increased.  This change of the main excretion route appeared to be 
associated with the change of Mrp2 transporter expression, because Mrp2 
mRNA expression in the liver was decreased and that in the kidney was 
increased in chronic hepatic failure (Fig. 3).  Wright et al. [21] clarified 
that the percentages of recovery of VPA-G in bile and urine of Wistar rats 
are about 63 and 23%, respectively, whereas those of Mrp2 transporter-
deficient rats (TR¯ rats) are 2 and 50%, respectively.  These results 
suggest that the excretion route of VPA-G changes predominantly from bile 
to urine as a result of compensatory changes in the expression of Mrp2 in 
liver and kidney.   
Thus, in summary, the AUC0-360 value of VPA was decreased 
significantly owing to the induction of Mrp2 expression in the kidney and 
the inhibition of enterohepatic circulation in rats with chronic hepatic 
failure.  However, the change of the disposition kinetics of VPA via this 
phase II reaction appears to be only slight compared with the changes in the 
disposition kinetics of drugs metabolized by phase I reactions involving 
14 
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Figure 1. Relative expression of UGT mRNA isoforms of liver (a) and 
duodenum (b) of untreated rats and rats with chronic hepatic failure. 
Rats were subcutaneously treated for 2 or 3 months with CCl4 (1.0 mL/kg, 
3 times a week).  The mRNA expression levels were determined at 48 h 
after the last treatment.  Each column and bar represents the mean ± sd of 
three rats.  
*,**Significantly different from the control rats at P<0.05 and 0.01, 
respectively. 
 , no treatment;   , CCl4 treatment for 2 months;    , CCl4 treatment 
for 3 months 
 
Figure 2. Relative enzyme activity of UGTs in hepatic microsomes of the 
untrated rats and rats with chronic hepatic failure.  Rats were 
subcutaneously treated for 2 or 3 months with CCl4 (1.0 mL/kg, 3 times a 
week ).  The activities were determined at 48 h after the last treatment. 
Each column and bar represents the mean ± sd of three rats.  
*,**Significantly different from the control rats at P<0.05 and 0.01, 
respectively. 
 , no treatment;   , CCl4 treatment for 2 months;    , CCl4 treatment 
for 3 months 
 
Figure 3. Relative expression of Mrp2 mRNA in liver and kidney of 
untreated rats and rats with chronic hepatic failure. 
20 
  
Rats were subcutaneously treated for 2 or 3 months with CCl4 (1.0 mL/kg, 
3 times a week).  The mRNA expression levels were determined at 48 h 
after the last treatment.  Each column and bar represents the mean ± sd of 
three rats.  
**Significantly different from the control rats at P< 0.01.  
 , no treatment;   , CCl4 treatment for 2 months;    , CCl4 treatment 
for 3 months 
 
Figure 4. Plasma concentration-time courses of VPA after intravenous 
administration of VPA (75 mg/kg) to control rats (  ) and rats treated with 
CCl4 for 2 (   ) or 3 months (   ).  Rats were subcutaneously treated for 
2 or 3 months with CCl4 (1.0 mL/kg, 3 times a week). VPA was 
administered at 48 h after the last treatment.  Each symbol and bar 
represents the mean ± sd of three rats.  
**Significantly different from the control rats at P< 0.01.  
 
Figure 5. Cumulative amounts of biliary (a) and urinary (b) excretion of 
VPA and VPA-G up to 6 h after intravenous administration in untreated rats 
and rats with chronic hepatic failure.  
Rats were subcutaneously treated for 3 months with CCl4 (1.0 mL/kg, 3 
times a week).  The rats were given VPA at 48 h after the last treatment.  
Each column and bar represents the mean ± sd of three rats.  
**Significantly different from the control rats at P< 0.01.  



















































































































































































































































































































































a) Bile b) Urine
                                          Untreated (control)                    CCl4-treated                                        
                                                                               2 months                   3 months               
AST (IU/L) a                           79 ± 7                 1874 ± 682f               1445 ± 845f             
ALT (IU/L) b                           42 ± 6                  335 ± 95f                    244 ± 156f         
ALP (IU/L) c                          943 ± 168            1687 ± 432e               1434 ± 243e           
Albumin (g/dL)                      3.64 ± 0.16            2.64 ± 0.23f                2.26 ± 0.62f                   
A/G ratio d                            2.16 ± 0.24             1.61 ± 0.23e               1.36 ± 0.25e            
Total bilirubin (mg/dL)         0.17 ± 0.06             0.71 ± 0.36f                0.89 ± 0.41f   
Data were determined at 48 h after the last treatment with CCl4 (1.0 mg/kg, 3 times a week).  
Each value represents the mean ± sd of three rats.  
a asparate aminotransferase;  b alanine aminotransferase; c alkaline phosphatase; d albumin/globulin 
ratio 
e, f Significantly different from control (untreated) rats at p<0.05 and 0.01, respectively.  
Table 1. Biochemical data for CCl4-treated rats
Rats were intravenously administered VPA (75 mg/kg).
Pharmacokinetic parameters were estimated according to model-independent moment analysis.
Each value represents the mean±sd of three rats.
a) area under plasma concentration-time curve from 0 to 8 h, b) mean residence time, c) total clearance,
d) distribution volume at the steady-state
** Significantly different from the untreated rats at P<0.05 and 0.01, respectively.
Table 2. Pharmacokinetic parameters for VPA
Parameter Untreated rats CCl4 for 2 M CCl4 for 3 M
AUC0-360 ( μg·min/mL) a) 16800±1030 10500±640** 13000±720**
MRT (min) b) 89.4±8.9 68.6±6.3* 71.5±6.7*
CLtot (mL/min/kg) c) 4.46±0.27 7.13±0.43** 5.75±0.32**
Vdss (mL/kg) d) 399±58 489±68 411±55
